EUSA Pharma Gets Untitled Letter for Promotion of Imaging Agent ProstaScint

Drug Industry Daily
A A
The FDA has handed an untitled letter to EUSA Pharma for promotional material that omitted contraindications and warnings about its prostate cancer diagnostic imaging agent.

To View This Article:

Login

Subscribe To Drug Industry Daily